1. Boiko AN, Boiko OV, Gusev EI. The choice of the optimal drug for pathogenic treatment of multiple sclerosis: a current state of the problem (a review). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2014;114:10(2):77-91. (In Russ.). https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova-2/2014/10/downloads/ru/031997-729820141040
2. Stolyarov ID. The modern methods of diagnostics and treatment of multiple sclerosis. Vestnik Roszdravnadzora. 2010;4:64-67. (In Russ.). https://elibrary.ru/download/elibrary_15195667_39522683.pdf
3. Karakulova YuV, Zhelnin AV, Trushnikova TN. Epidemiology and geography of multiple sclerosis in the Perm region. Vestnik Roszdravnadzora. 2013;2:43-45. (In Russ.)
4. Semaphorins 4A and 4D in chronic inflammatory diseases
5. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2